A unit of Malaysia's IHH Healthcare has lost its damages claim against Japanese drugmaker Daiichi Sankyo, according to The Edge Malaysia. The Tokyo court dismissed the claim, which sought ¥200 billion, the outlet reported on Thursday.
Reuters, also citing the ruling, identified the dispute as tied to the Fortis deal and said the Malaysian group's unit brought the case in Tokyo. TradingView reported that Daiichi Sankyo received a favorable judgment in the claim filed by NTK, while MarketScreener put the disputed sum at 203.3 billion yen. The Star likewise reported that the Tokyo court threw out the IHH unit's claims against Daiichi Sankyo.
The reports did not detail the court's reasoning or the full background of the dispute. The case centers on IHH's unit and Daiichi Sankyo, with the Fortis transaction cited as the underlying matter.
IHH Healthcare is a Malaysian hospital operator, and Daiichi Sankyo is a Japanese pharmaceutical company. The claim was heard in Tokyo.
What to watch next: whether the IHH unit appeals the ruling, and whether either company issues a statement on the decision.
